United Development Funding IV and United Development Funding Income Fund V Announce Distributions for Q1 2021

GRAPEVINE, Texas, March 15, 2021 (GLOBE NEWSWIRE) — United Development Funding IV (“UDF IV”) announced today that on March 11, 2021 its board of trustees authorized a cash distribution of $0.065 per share payable on March 31, 2021 to shareholders of record at the close of business on March 24, 2021.

United Development Funding Income Fund V (“UDF V”) also announced today that on March 11, 2021 its board of trustees authorized a cash distribution of $0.254 per share payable on March 31, 2021 to shareholders of record at the close of business on March 24, 2021.

About United Development Funding IV

United Development Funding IV is a Maryland real estate investment trust. UDF IV was formed primarily to generate current interest income by investing in secured loans and producing profits from investments in residential real estate. Additional information about UDF IV can be found on its website at www.udfiv.com. UDF IV may disseminate important information regarding its operations, including financial information, through social media platforms such as Twitter, Facebook and LinkedIn.

About United Development Funding Income Fund V

United Development Funding Income Fund V is a Maryland real estate investment trust. UDF V was formed primarily to generate current interest income by investing in secured loans and producing profits from investments in residential real estate. Additional information about UDF V can be found on its website at www.udfincomefundv.com. UDF V may disseminate important information regarding its operations, including financial information, through social media platforms such as Twitter, Facebook and LinkedIn.

Investor Contact:

Investor Relations
1-800-859-9338
[email protected]

Media Contact:

[email protected]

817-835-0650



SOLIZE and HP Enable Sustainable 3D Production of Replacement NISMO Heritage Parts

  • Leading digital manufacturer SOLIZE partnering with HP Inc. on joint development of replacement parts for NISMO Heritage Parts
  • SOLIZE and HP first to deliver highly efficient, industrial-grade, and cost-effective just-in-time production of replacement parts for NISMO enthusiasts
  • 3D printed parts include plastic harness protector for R32 Nissan Skyline GT-R
  • SOLIZE, HP and Nissan share commitment to sustainable production, finding innovative ways to reduce, reuse and recycle.

TOKYO, March 15, 2021 (GLOBE NEWSWIRE) — SOLIZE Corporation and HP Inc. continuing their long-standing partnership to advance digital manufacturing, today announced the joint development and on-demand production of discontinued replacement parts for Nissan’s NISMO Heritage Parts program. The two companies are the first to design and manufacture 3D-printed replacement parts for NISMO enthusiasts.

After working with Nissan to identify ideal parts for 3D production, SOLIZE then partnered with HP to optimize high-quality commercial parts and take advantage of the advanced capabilities provided by HP’s Multi Jet Fusion platform for production. The first part identified for restoration using 3D printing is a plastic part of the harness protector for the R32 Nissan Skyline GT-R. The part is produced using HP High Reusability PA 11 which provides high mechanical properties and design flexibility.

“SOLIZE has more than 30 years of experience and has honed its technology since it first deployed 3D printers in Japan.” said Yasutoshi Kudo, President & CEO, SOLIZE Corporation. “We have jointly developed 3D printing technology with Nissan for commercial parts that have been discontinued and take charge of manufacturing the parts. With HP’s market leading 3D printing technology, we are able to support industries including automotive with sustainable production that delivers fast, high-quality and cost-effective results.”

Rebuilding Supply Chains with Sustainable Production

To facilitate repairs and parts replacement, automobile manufacturers are required to provide replacement parts for their products over extended periods of time. Producing or storing parts for vehicles that have been discontinued, upgraded, or overhauled can be challenging and expensive as manufacturers must retain molds and manage inventory storage and logistics.

Digital manufacturing and 3D printing enable flexible design and just-in-time 3D production for virtual inventory that meets the demand for complex parts while reducing costs. In addition, sustainable on-demand 3D production contributes to the reduction of industrial waste and carbon dioxide emissions throughout the product life cycle.

“We are seeing leaders of industry like Nissan recognize the massive cost implications of storage, molds and logistics for replacement parts and how industrial 3D printing can help,” said Jon Wayne, Head of Global Commercial Business for 3D Printing and Digital Manufacturing, HP Inc. “Digital manufacturing is a viable, long-term solution for accelerating production, transforming supply chains and activating industries such as automotive. Together with SOLIZE we are focused on helping businesses transform their manufacturing with sustainable, digital production.”

About NISMO Heritage Parts

In response to the expansion of the global heritage market and the increasing demand from customers for support parts and maintenance, Nissan is continually looking to evolve its NISMO Heritage Parts. Sales of NISMO Heritage Parts began in December 2017, providing customer support, maintenance, and restoration options for Nissan Heritage cars no longer in production. To help Nissan meet the needs of its customers, SOLIZE and HP will support the development of replacement parts for the Skyline GT-R R32/R33/R34.

“Our Heritage customers are the most passionate car enthusiasts in the world, and we are dedicated to ensuring they can enjoy their cars as long as possible,” said Kent O’Hara, Senior Vice President, Nissan Motor Co., Ltd. “We are excited that SOLIZE and HP can help us please our customers and achieve our goals in a sustainable way.”

About SOLIZE

SOLIZE has been a leader in digital engineering technology since the dawn of 3D CAD in the 1990s, when it started rapid prototyping and 3D modeling using 3D printers, as well as 3D CAD engineer education and 3D CAD engineering services. Currently, SOLIZE provides 3D CAD/CAE engineering services for product design and analysis, MBD engineering services for model-based development, 3D printing engineering services for the production of prototypes, low-volume mass-produced products using additive manufacturing (metal and plastic) and sales of industrial additive manufacturing equipment and innovations engineering services to reform customer’s business and/or development process based on our unique technology of transforming tacit knowledge into formal knowledge. Through our four core businesses, we provide valuable services to our customers.

About HP Inc.

HP Inc. (NYSE: HPQ) creates technology that makes life better for everyone, everywhere. Through our product and service portfolio of personal systems, printers and 3D printing solutions, we engineer experiences that amaze. More information about HP Inc. is available at www.hp.com.



Michele Guthrie
HP Inc.
[email protected]

Castellum, Inc. Provides ONOV Shareholders an Update Letter

BETHESDA, Md., March 15, 2021 (GLOBE NEWSWIRE) — Castellum, Inc. (ONOV: OTC) today provides the following Corporate letter updating its shareholders:

Dear Fellow Shareholders,

As we approach spring and the winding down of the Covid-19 health crisis, we at Castellum are pleased to share with you this update. Much has been accomplished already this year and we have more to come.

We have finished our second full annual audit by RSM. Our 2020 revenue came in at $13.3 million, up over 20% versus comparable 2019 numbers. Our business development at our subsidiary Corvus has significantly ramped-up, as Jim Enicks and his team have built over a $300 million 5-year qualified pipeline of opportunities for future growth. While we will not close all of that business, we should get our fair share – and a reasonable share will lead to continued growth in Corvus’s business. We anticipate generating at least $15.3 million in revenue at Corvus this year, and over $20 million in 2022. While net income on a GAAP basis is still negative as we amortize certain intangible assets, operating profit excluding non-cash stock compensation was a solid $1.3 million in 2020. We expect that number to increase in 2021. Completing a second year of audits positions, Castellum could potential up-list our stock to the NYSE MKT or other suitable exchange once we exceed $25 million in revenue.

On February 2, 2021, Castellum welcomed Glen Ives, formerly the President and CEO of Sabre Systems, as the Chief Growth Officer and CEO of Castellum’s newly formed Navy and Marine Corp Division. Glen grew his previous company from $40 million to $80 million during his tenure and brings with him acquisition targets and key customer relationships in the Navy/Marine Corps as well as other non-DoD entities. Investing in human capital that can grow our business at all levels will remain a key element to our continued success.

Also, in February 2021, we restructured and extended our promissory note with Laurie Buckhout, the former owner of Corvus, pushing the maturity out to 2024 and starting to amortize the principal of that loan. Combined with our growing cash levels, our balance sheet continues to strengthen. Net working capital increased from $1.6 million at year-end 2019 to $2.9 million at year-end 2020.

On January 1, 2021, Castellum acquired MFSI Government Group in an all-stock transaction. MFSI through its CEO, George Tronsrue, brings to Castellum past performance in software engineering and strong customer and prime contractor relationships. The past performance has enabled our Corvus subsidiary to pursue multiple new opportunities with existing and new customers. MFSI adds approximately $2 million in profitable revenue to Castellum.

So, as you can see, we have already had some significant wins this year. Going forward, we have several additional goals for 2021. As mentioned, we expect to see strong 15%+ organic growth at Corvus this year. Glen Ives is expected to start construction of a Navy division. Also, MFSI will serve as a catalyst for additional growth, and we are working on our next acquisition. We have financing sources already in position, both senior lenders and mezzanine capital. There are over a dozen potential acquisitions under review with a couple that we especially like. We hope to sign an LOI for our next deal within the next 90 days. The roadmap, therefore, is to do our next acquisition and then look at up-listing.

Thank you to all of our employees, shareholders, and partners for a terrific 2020. 2021 and the future promise to be even brighter.

About Castellum, Inc. 


Castellu


m




, Inc.
 
(OTC: ONOV) is a technology services and solutions company executing strategic acquisitions in Cyber Security, Information Technology, Information Warfare, Electronic Warfare, Systems Engineering, Software Engineering and Software Development. The Company recently acquired MFSI after purchasing Corvus Consulting in 2019. The Company continues in discussions with multiple acquisition candidates and, also, has numerous efforts ongoing as a potential prime contractor for multiple customers.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters disclosed at www.otcmarkets.com. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements. 

Mark Fuller, CEO 
[email protected] 
301-961-4895 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f0b3bcc-8994-4f23-8503-e20b61196308



Shift Technologies Appoints Retail Industry Veteran, Oded Shein, as Chief Financial Officer

SAN FRANCISCO, March 15, 2021 (GLOBE NEWSWIRE) — Shift (NASDAQ: SFT), a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience, today announced the appointment of Oded Shein as the company’s Chief Financial Officer (CFO), responsible for all Finance, Accounting and Business Operations functions.

Mr. Shein has extensive public company experience in the retail industry. He served as CFO of Stage Stores for seven years and is presently a Board Member and Chair of the Audit Committee at Conn’s HomePlus. He has also served as CFO of The Fresh Market and in senior finance roles at Belk and Charming Shoppes. Mr. Shein will oversee a team led by other experienced finance professionals, including Controller and Senior Vice President Blima Tuller and Vice President of FP&A and Business Operations Julie Zarenko.

“We are very excited to have Oded join the organization as we continue to execute our strategy and build value for our customers, employees and shareholders,” said George Arison, Shift’s co-founder and co-CEO. “His extensive experience as a public company CFO, his financial expertise and his proven leadership qualities will be an invaluable addition to the team.”

“I am thrilled to be joining Shift after the record-breaking year they had in 2020, and I feel privileged to have this opportunity to serve Shift’s customers, teammates, community and shareholders,” said Mr. Shein.

Mr. Shein will be taking over for Cindy Hanford, who will be stepping down after serving as the finance leader at Shift since October 2019. Mr. Shein’s appointment will be effective upon the filing of the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Ms. Hanford will stay on as a consultant to Shift to assist with the transition through April 21, 2021.

“On behalf of our Board of Directors and everyone at Shift, I thank Cindy for her exceptional leadership and contribution as our CFO over the past year. She led our finance operation as we transitioned to a publicly held company and built a strong finance team. Cindy has made a valuable contribution to Shift, a foundation from which we build as we grow Shift” said Toby Russel, co-founder and co-CEO.

About Shift

Shift is a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience. Shift’s mission is to make car purchase and ownership simple — to make buying or selling a used car fun, fair, and accessible to everyone. Shift provides comprehensive, digital solutions throughout the car ownership lifecycle: finding the right car, having a test drive brought to you before buying the car, a seamless digitally-driven purchase transaction including financing and vehicle protection products, an efficient, digital trade-in/sale transaction, and a vision to provide high-value support services during car ownership. For more information please visit www.shift.com.

Investor Relations Contact:

Drew Haroldson, The Blueshirt Group
[email protected]

Media Contact:

Jeff Fox, The Blueshirt Group
[email protected]

Source: Shift Technologies, Inc.



Adamis Pharmaceuticals Announces Tempol Reduces Lung Inflammation in the COVID-19 Challenged Hamster Model

SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) — Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) (“Company”) announced today that in studies conducted at Galveston National Laboratory (GNL), University of Texas Medical Branch (UTMB) at Galveston, hamsters challenged with the virus that causes COVID-19 (SARS-CoV-2), resulted in decreased inflammation in the lungs of animals treated with Tempol compared to controls. This is the first data demonstrating that Tempol, a novel antioxidant, can reduce inflammation in animals given the virus (SARS-CoV-2) that causes COVID-19. The group plans on submitting the publication to a peer review journal.

Dr. Chien-Te Kent Tseng, Professor of the Department of Microbiology and Immunology and Director of GNL’s SARS/MERS/COVID-19 Laboratory at UTMB, commented on these results: “In our hamster COVID-19 model, pulmonary inflammation with cellular infiltrates and hemorrhage (mild-to-moderate) is triggered by SARS-CoV-2 infection. Treatment with Tempol reduces the overall inflammatory responses and appears to start repairing damaged lungs.”

These results are also consistent with the results that the Company announced regarding in-vitro cytokine data from Stanford University. The results demonstrated that incubation of Tempol significantly suppresses multiple inflammatory cytokines from cells taken from COVID-19 patients.

Tempol has demonstrated both potent anti-inflammatory, anticoagulant, and antioxidant activity. Both inflammatory cytokines and reactive oxygen species (ROS) from cells of the immune system called macrophages and neutrophils damage the lung in Acute Respiratory Distress Syndrome (ARDS). Tempol has now been shown to: (1) Decrease the proinflammatory cytokines (cytokine storm) in animal models (lipopolysaccharide induced), (2) Suppress cytokines in stimulated COVID-19 positive human cells, and (3) Reduce inflammation in hamsters challenged with COVID-19. In addition, Tempol has been shown to decrease platelet aggregation, a problem observed in many COVID-19 patients.

The new results demonstrating decreased lung inflammation in hamsters challenged and treated with Tempol are consistent with the design of the recent FDA allowed IND and protocol to study Tempol in early COVID-19 infection. The goal of the study titled, “A Phase 2/3, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study to Examine the Effects of Tempol (MBM-02) on Preventing COVID-19 Related Hospitalization in Subjects with COVID-19 Infection” is to examine the safety and activity of Tempol in COVID-19 patients early in the infection. In addition to safety, the study will examine markers of inflammation and the rate of hospitalization for patients taking Tempol versus placebo early in COVID-19 infection. More details of the protocol can be found here or by searching Clinicaltrials.gov. Dr. Ronald Moss, Chief Medical Officer of Adamis, commented: “These results from a validated animal model for COVID-19 provide further support on implementing our well-designed clinical trial in order to obtain activity and safety information on the use of Tempol in early COVID-19 infection in humans.”

Dr. Dennis J. Carlo, President and Chief Executive Officer of Adamis Pharmaceuticals, commented: “The results to date support the design of our clinical study in that we are targeting early infection with the objective of reducing lung inflammation and eventual hospitalization. We are hopeful that the clinical study will replicate the results obtained to date, i.e., preventing or ameliorating some of the most severe symptoms of COVID-19 caused by dysfunctional inflammation.”

In addition to Dr. Tseng, the UTMB team includes Drs. Aleksandra K. Drelich, Kempaiah Rayavara Kempaiah, and Bi-Hung Peng (Pathologist).

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company’s SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company’s subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States.
   
Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including, but not limited to the following statements: the company’s beliefs concerning the safety and effectiveness of Tempol or the company’s other product candidates; the timing of commencement or completion of studies or trials relating to Tempol; the results of any studies or trials that the company may conduct relating to Tempol; the company’s ability to commercialize the product candidates described in this press release, itself or through commercialization partners; and other statements concerning our future operations and activities. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from the results anticipated by such forward-looking statements. There can be no assurances regarding the timing of commencement of trials relating to Tempol, the timing of completion of such trials or the outcome of such trials, that the company’s planned Phase 2/3 study will produce results that are consistent with earlier preclinical or clinical studies or trials relating to Tempol, or that Tempol will be found to be safe and effective in the treatment of COVID-19 or any other indication. We cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances arising after the date of this press release. Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, including its most recent annual report on Form 10-K and subsequent filings with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at http://www.sec.gov.

Contact Adamis

Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
[email protected]



Marksmen Announces Its 2021 Drilling Program with the Continuation of Its Strategic 40 Well Recomplete Program and Other Development Opportunities in Ohio, USA

CALGARY, Alberta, March 15, 2021 (GLOBE NEWSWIRE) — Marksmen Energy Inc. (“Marksmen” or the “Company”) (TSXV: MAH) (OTCQB: MKSEF) is pleased to announce the following:

Portage County, Ohio – Marksmen has a Joint Operating Agreement with PEP Drilling LLC (“PEP”) of Ohio, to recomplete up to 40 Clinton Sandstone formation wells in Portage County, Ohio. Under the terms of the agreement Marksmen would pay 100% of the capital costs to earn an 80% working interest until 125% of capital payback is reached.

The Clinton Sandstone is historically one of the most prolific producing formations in Ohio, spread over several counties, with many thousands of wells drilled. The recompletes in this 40 well program are in wells that originally targeted a deeper zone and bypassed the Clinton Sandstone formation entirely and left it untapped. Management believes the geological risk with these wells is minimal.

The Ryan #1 well is the second well under this program. On March 9, 2021, a service rig commenced work on recompleting this well. It has approximately 70 feet of pay in the Clinton Sandstone formation at a target depth of approximately 4,500 feet. It is expected that the recomplete program will take approximately two weeks. Once the Ryan well is completed and production tested successfully, the service rig will then move to the third location in the 40 well program. The plan is for back-to-back, continuous development of this program.

Marksmen is also in discussions with operators to drill one or more Rose Run vertical or horizontal wells. There are many analogous wells in the area that show initial production in the Rose Run in the 100 bbl per day range. The Marksmen management team is working to expand this runway of opportunity significantly in the next six months. More details on the expansion will be announced as they are contracted.

Pickaway County, Ohio – Marksmen is completing initial work including surveying, state permitting etc. to drill the first of up to five vertical offset wells to Marksmen’s Davis Holbrook #1 (“DH-1”). Marksmen holds a 75% working interest. The DH-1 is Marksmen’s best well, drilled in 2016, with initial production in the 80 bbls of oil per day range. It has since produced over 47,000 bbls of oil and continues to produce at approximately 25 bbls of oil production per day. The Davis Holbrook #2 (DH-2) offset, also on a 3D Seismic Cambrian Knox formation high, is also expected by management to be a strong, productive well. We anticipate that drilling operations will commence in early to mid-April. The well will be tied-in to the existing surface infrastructure currently in place for the DH1 well.

Other Ohio opportunities – Marksmen’s technical management team in Ohio has developed contacts with several Ohio operators and consulting geologists who have brought several promising Rose Run, Knox and other joint venture opportunities to the Company that are currently in the process of being evaluated and prioritized.   

Marksmen receives WTI pricing for its Pennsylvania Grade Light Oil that is in high demand for use in specialty products. Refineries purchase the oil at Marksmen’s well locations and Marksmen has no transportation or storage costs. A recent annual study of the industry by KPMG confirms that Marksmen’s operating net backs are among the highest in the industry.

Archie Nesbitt, President and Chief Executive Officer of Marksmen states “The resurgence of the West Texas Intermediate oil price (“WTI”) to over $60 US per barrel will invigorate the Ohio oil industry and Marksmen is well positioned through our strong technical management team and contacts in Ohio to embark on new and exciting projects.
The Company has already been approached by a number of attractive proposals that are in the process of being evaluated and prioritized.”

For additional information regarding this news release please contact Archie Nesbitt, Director and CEO of the Company at (403) 265-7270 or e-mail [email protected].

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

This news release may contain certain forward-looking information and statements, including without limitation, statements pertaining to the future drilling program and timing. All statements included herein, other than statements of historical fact, are forward-looking information and such information involves various risks and uncertainties. There can be no assurance that such information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such information. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Marksmen’s disclosure documents on the SEDAR website at www.sedar.com. Marksmen does not undertake to update any forward-looking information except in accordance with applicable securities laws.



GeoVax to Report 2020 Financial Results on Tuesday, March 23, 2021 and Provide Corporate Update

Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern Time

ATLANTA, GA, March 15, 2021 (GLOBE NEWSWIRE) — via NewMediaWire  — GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, announces today that it plans to report 2020 financial results on Tuesday, March 23, 2021 after the market closes.

Management will host a conference call at 8:00 a.m. ET on Wednesday, March 24, 2021 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call via the following link: https://dpregister.com/sreg/10152894/e3a3a9bd2c

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-777-2509 (domestic) or 1-412-317-5413 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the GeoVax Labs call. 

The conference call will be available through a live webcast found here:


https://services.choruscall.com/links/govx210324.html

A webcast replay of the call will be available approximately one hour after the end of the call through June 24, 2021.  The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10149661. The telephonic replay will be available until April 7, 2021.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. 

GeoVax’s current development programs are focused on preventive vaccines against COVID-19, HIV, Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa), and malaria, as well as therapeutic vaccines against multiple cancers. The Company has designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the commercial markets of the Americas, Western Europe, Japan, and Australia; human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of two separate collaborative efforts to apply its innovative gene therapy approach toward a functional cure for HIV.


Cautionary Note Regarding Forward-Looking Statements

This release and the related conference call contain forward-looking statements regarding GeoVax’s business plans and financial resuls.. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, the impact of the COVID-19 pandemic continues, and other factors, over which GeoVax has no control.

GeoVax Labs, Inc.
678-384-7220
[email protected]



Norsemont Provides Update on Choquelimpie Gold-Silver Project

VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) — Norsemont Mining Inc. (CSE: NOM, OTCQB: NRRSF, FWB: LXZ1) (“Norsemont” or the “Company”) wishes to provide an update to its shareholders on the Choquelimpie gold-silver project (“the Project”), located within the Province of Parinacota in Region XV of northern Chile and approximately 115 kilometers east-northeast of the coastal city and port of Arica. Norsemont holds a 100% ownership interest in the project, through its wholly owned Chilean subsidiary Sociedad Contractual Minera Vilacollo, (“SCM Vilacollo”).

Norsemont is pleased to report that critical in-country management and staff positions have been filled with the technical team being led by Mr. John Currie, VP Exploration.

Until recently field operations have been challenging due to Covid-19 lock-downs but Norsemont is now pleased to report that field operations are now underway in earnest, whilst continuing to carefully observe Covid-19 protocols. Meetings have been held with local indigenous community leaders and access agreements are in place.

With regard to environmental matters the company has completed a review of leading consultants in Chile and selected DAES Consultores (“DAES”) of Santiago, to assist in the development, analysis and formulation of appropriate environmental strategies and ensure compliance for the project. DAES management has more than 20 years of experience in environmental matters across various industries.

On the technical front the early focus has been on developing a comprehensive validated database. Voluminous historic material is being digitized and a major re-assaying program is underway. Diamond drill core, RC cuttings pulps and splits are kept in an orderly fashion in a warehouse at the historic mine-site and are easily accessible. Several thousand samples will be re-assayed over the next three months and results will be compared to historic data with the aim of supporting a compliant 43-101 resource.   

Marc Levy, CEO of Norsemont said, “We are pleased to back in the field at Choquelimpie and look forward to rapidly moving the project forward with a plan for additional drilling, subject to permitting, and delivering a NI 43-101 compliant resource, in the second half of the year.”

On behalf of the Board of Directors,
NORSEMONT MINING INC.

Marc Levy
CEO & Chairman

For more information, please contact the Company at:
Telephone: (604) 669-9788; Facsimile: (604) 669-9768

Forward-Looking Information

This release includes certain statements that are deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that Norsemont expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include changes to commodity prices, mine and metallurgical recovery, operating and capital costs, foreign exchange rates, ability to obtain required permits on a timely basis, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. 



Patagonia Exercises Option to Acquire Latin Metals’ Mina Angela Project, Chubut Province, Argentina

VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) —  Latin Metals Inc. (“Latin Metals” or the “Company”) – (TSXV: LMS)(OTCQB: LMSQF) announces that it has received an option exercise notice from Patagonia Gold Corp. (“Patagonia”), pursuant to an option agreement (the “Option Agreement”) among Patagonia, Latin Metals and an Argentine subsidiary of Latin Metals, whereby Patagonia was granted an irrevocable option (the “Option”) to acquire a 100% interest in the Mina Angela project (the “Project” or “Mina Angela”), located in the Province of Chubut, Argentina.

In connection with exercise of the Option, Patagonia (through its subsidiary) will make a cash payment to Latin Metals of US$250,000 pursuant to the terms of the Option Agreement, which payment is due on or before March 26, 2021 (Table 1). Pursuant to the terms of the Option Agreement, Latin Metals will be entitled to receive a 1.25% net smelter returns royalty (“Royalty”) from future production on the Project, half of which Royalty can be repurchased by Patagonia from Latin Metals at any time for US$1 million.


Table 1: Schedule of Commercial Terms

Schedule of Payments Cash Payments Royalty Payments Cumulative Earned Interest
Within ten days from acceptance of the Offer Letter US$40,000 (paid) — —  
Additional payment as consideration for extension of the due diligence period US$50,000 (paid) — —  
Advance on First Option Payment US$50,000 (paid) — —  
First Option Payment – Upon signing Option Agreement – September 12, 2020 US$200,000 (paid) — —  
Second Option Payment – Upon exercise of the Option – due on or before March 26, 2021 US$250,000 — 100 %
Final Payment1 US$500,000 — 100 %
Commencement of Production at the Project — 1.25% NSR Royalty 100 %

Notes:

1. Within thirty (30) days from the lifting of the Chubut Province mining bans in such a manner that Patagonia thereafter has the ability to perform exploration and exploitation mining activities on the Project, irrespective of whether Patagonia has obtained the required permits for such exploration and mining activities or the actual performance of such activities.

“Patagonia’s purchase of Mina Angela is consistent with Latin Metals’ strategy to joint venture core assets and where possible to monetize non-core assets, like Mina Angela, while keeping a retained royalty interest, in this case a 1.25% Royalty,” stated Keith Henderson, Latin Metals’ President and CEO. “Receipt of US$250,000, together with a contingent future payment of US$500,000 will conclude the US$1,090,000 disposition of the Mina Angela asset. We would like to wish Patagonia’s management team every success in moving the project forward.”


About the Mina Angela Property

The Mina Angela property is situated in the Somuncura Massif of southern Argentina and is comprised of 44 individual claims located approximately 50 km east-southeast of Patagonia’s 100% owned Calcatreu gold project. The Navidad silver and base metal deposit is located 45 km further to the south-southeast of Mina Angela.


About Patagonia Gold

Patagonia Gold Corp. is a mining and development company listed on the TSX Venture Exchange. The Company seeks to grow shareholder value through exploration and development of gold and silver projects in the Patagonia region of Argentina. The Company is primarily focused on the Calcatreu project in Rio Negro and the development of the Cap-Oeste underground project. Patagonia, indirectly through its subsidiaries or under option agreements, has mineral rights to over 360 properties in several provinces of Argentina and Chile and is one of the largest landholders in the Province of Santa Cruz, Argentina.


About Latin Metals

Latin Metals is a mineral exploration company with a diversified portfolio of gold and copper exploration assets in South America. The Company operates with an investor-focused Prospect Generator model, which brings potential advantages to shareholders such as exposure to multiple exploration projects reducing discovery risk. Most of the exploration expense could be borne by JV partners, potentially reducing dilution associated with funding ongoing exploration activities. The Company’s project portfolio brings exposure to multiple commodities, reducing the impact associated with commodity price cycles. In all future property agreements, the Company intends to retain a minority interest across the portfolio, providing shareholders with exposure to potential discovery upside.


Qualified Person

Keith J. Henderson, P.Geo., is the Company’s qualified person as defined by NI 43-101 and has reviewed the scientific and technical information that forms the basis for portions of this news release. He has approved the disclosure herein. Mr. Henderson is not independent of the Company, as he is an employee of the Company and holds securities of the Company.

On Behalf of the Board of Directors of

LATIN METALS INC.

“Keith Henderson”

President & CEO

For further details on the Company readers are referred to the Company’s web site (www.latin-metals.com) and its Canadian regulatory filings on SEDAR at www.sedar.com.

For further information, please contact:

Keith Henderson

Suite 2300
1177 West Hastings Street
Vancouver, BC, V6E 2K3

Phone: 604-638-3456
E-mail: [email protected]

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.


Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, statements regarding the remaining Option payments payable by Patagonia to Latin Metals pursuant to the Option Agreement, the Company’s expectation that it will be able to operate as a Prospect Generator by entering into agreements to acquire interests in additional mineral properties and attracting joint venture partners to fund drilling and conduct advanced exploration on its properties, the discovery and delineation of mineral deposits/resources/reserves on its properties, the
anticipated results from exploration activities and the anticipated business plans and timing of future activities of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved.   In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future development of the Company’s Argentine projects in a timely manner, including the lifting of restrictions preventing the development of mining activities at Mina Angela, the availability of financing on suitable terms for the development, construction and continued operation of the Company’s projects, and the Company’s ability to comply with environmental, health and safety laws.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, actual results of exploration activities, that Patagonia will be satisfied with the lifting of the mining restrictions in the
Chubut Province such that it makes the final Option payment to the Company, the inability of the Company to operate as a Prospect Generator and enter into agreements to acquire interests in additional mineral properties and attract joint venture partners for the exploration and development of same, operating and technical difficulties in connection with mineral exploration and development and mine development activities at the Company’s mineral properties, the fact that the Company’s interests in certain of its mineral properties are only options and there is no guarantee that the interests, if earned, will be certain, requirements for additional capital, future prices of precious metals, copper-gold and lithium, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, social and economic impacts of COVID
‐
19, other risks of the mining industry, the inability to obtain any necessary governmental and regulatory approvals (including TSX Venture Exchange acceptance for filing of any current or future property acquisitions or dispositions), financing or other planned activities, changes in laws, regulations and policies affecting mining operations, hedging practices and currency fluctuations, title disputes or claims limitations on insurance coverage and the timing and possible outcome of pending litigation, environmental issues and liabilities, risks related to joint venture operations, and risks related to the integration of acquisitions, as well as those factors discussed under the heading “Risks and Uncertainties” in the Company’s most recent management’s discussion and analysis and other filings of the Company with the Canadian Securities Authorities, copies of which can be found under the Company’s profile on the SEDAR website at

www.sedar.com

.

Readers are cautioned not to place undue reliance on forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to update any of the forward-looking information in this news release or incorporated by reference herein.



Flexion Therapeutics to Present at the Oppenheimer 31st Annual Virtual Healthcare Conference

BURLINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) — Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Oppenheimer 31st Annual Healthcare Conference. The virtual fireside chat is scheduled to begin at 10:00 a.m. ET on Wednesday, March 17, 2021.

To access the live webcast of the presentation, please visit the Flexion website at http://ir.flexiontherapeutics.com.

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company’s core values are focus, ingenuity, tenacity, transparency and fun. Please visit flexiontherapeutics.com.

Contact:

Scott Young
Vice President, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]